Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480

Clinical Genitourinary Cancer

Volumn 4, Issue 4, 2006, Pages 269-274

  Humphrey, Peter A ^a   Halabi, Susan ^b   Picus, Joel ^a   Sanford, Ben ^b   Vogelzang, Nicholas J ^c   Small, Eric J ^d   Kantoff, Philip W ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University of Chicago   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

c Met; NK4; Prognosis; Suramin

Indexed keywords

ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 33646862208     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.006     Document Type: Article

References (53)

1. Netto GJ, Humphrey, PA. Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 1994; 102:S57-S64.
2. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998; 44:705-723.
3. Cunha GR, Hayward SW, Dahiya R, et al. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat 1996; 155:63-72.
4. Grossfeld GD, Hayward SW, Tlsty TD, et al. The role of stroma in prostatic carcinogenesis. Endocr Relat Cancer 1998; 5:253-270.
5. Chung LW. The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 1995; 23:33-42.
6. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995; 153:1085-1096.
7. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150-160.
8. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002; 89:230-240.
9. Jiang W, Hiscox S, Matsumoto K, et al. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999; 29:209-248.
10. Parr C, Jiang WG. Hepatocyte growth factor activators, inhibitors, and antagonists and their implication in cancer intervention. Histol Histopathol 2001; 16:251-268.
11. Maulik G, Shrikhande A, Kijima T, et al. Role of hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13:41-59.
12. Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003; 327:1-23.
13. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147:386-396.
14. Nishimura K, Kitamura M, Miura H, et al. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate 1999; 41:145-153.
15. Tsuka H, Mori H, Li B, et al. Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy. Int J Oncol 1998; 13:169-176.
16. Kurimoto S, Moriyama N, Horie S, et al. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998; 30:27-32.
17. Wolf HK, Zarnegar R, Michalopoulos GK. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 1991; 14:488-494.
18. Nakashiro K, Okamoto M, Hayashi Y, et al. Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am J Pathol 2000; 157:795-803.
19. Gmyrek GA, Walburg M, Webb CP, et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001; 159:579-590.
20. You X, Yu HM, Cohen-Gould L, et al. Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stroma cells. Exp Cell Res 2003; 288:246-256.
21. Inoue K, Chikazawa M, Karashima T, et al. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma. Acta Med Okayama 1998; 52:305-310.
22. Krill D, Shuman M, Thompson MT, et al. A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 1997; 49:981-988.
23. Pisters LL, Troncoso P, Zhau HE, et al. c-MET proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995; 154:293-298.
24. Wantanabe M, Fukutome K, Kato H, et al. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999; 141:173-178.
25. Lang SH, Clarke NW, George NJ, et al. Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Clin Exp Metastasis 1999; 17:333-340.
26. Tsuka H, Mori H, Li B, et al. Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int J Oncol 1998; 13:927-934.
27. Van Leenders G, van Balken B, Alders T, et al. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002; 51:98-107.
28. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002; 60:1113-1117.
29. Nakashiro K, Hara S, Shinohara Y, et al. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma line, CWR22R. Am J Pathol 2004; 165:533-540.
30. Davies G, Jiang WG, Mason MD. Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. J Urol 2000; 163:985-992.
31. Hall CL, Tsan R, Mugnai G, et al. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 2004; 59:167-176.
32. Zhu X, Humphrey PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000; 56:1071-1074.
33. Naughton M, Picus J, Zhu X, et al. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001; 165:1325-1328.
34. Small EJ, Halabi S, Ratain MJ, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol 2002; 20:3369-3375.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
36. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trial requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1979; 35:1-39.
37. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Ana 2003; 43:121-137.
38. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc 1974; B74:187-220.
39. Gohji K, Nomi M, Niitani Y, et al. Independent prognostic value of serum hepatocyte growth and factor in bladder cancer. J Clin Oncol 2000; 18:2963-2971.
40. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003; 72:229-233.
41. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-1237.
42. Jones A, Fujiyama C, Turner K, et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000; 85:276-280.
43. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7:1932-1936.
44. Cronauer MV, Hittmair A, Eder IE, et al. Basic fibroblast growth factor levels in cancer cells and in the sera of patients suffering from proliferative disorders of the prostate. Prostate 1997; 31:223-233.
45. Shariat SF, Andrews B, Kattan MW, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58:1008-1015.
46. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999; 91:1548-1556.
47. Date K, Matsumoto K, Kuba K, et al. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1996; 17:3045-3054.
48. Davies G, Mason MD, Martin TA, et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate growth and angiogenesis in vivo. Int J Cancer 2003; 106:348-354.
49. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001; 98:7443-7448.
50. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6:61-73.
51. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2003; 2:1085-1092.
52. Christensen JG, Schrek R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63:7345-7355.
53. Sattler M, Pride YB, Ma P, et al. A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003; 63:5462-5469.